Turning patient care inside out.
To improve patient lives and reduce healthcare costs by enabling and enhancing outpatient management of acute conditions with innovative therapeutic solutions.
At scPharmaceuticals, we are focused on exploring, developing, and commercializing innovations that will expand and advance the outpatient care of acute conditions – including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Our goal is to provide targeted solutions for patient populations and disease states where outpatient management will have the greatest impact.
In this pursuit, we are committed to reducing the systemic financial and physical constraints inherent in the highest-cost setting for treatment—the hospital.
We believe the most significant advances in outpatient care will be achieved by applying state-of-the-art science and technologies to current treatment options. In developing unique, ground-breaking approaches, we hope to transform the experience of physicians, patients, caregivers and payors.
To improve patient lives and reduce healthcare costs by enabling and enhancing outpatient management of acute conditions with innovative therapeutic solutions.
At scPharmaceuticals, we are focused on exploring, developing, and commercializing innovations that will expand and advance the outpatient care of acute conditions – including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Our goal is to provide targeted solutions for patient populations and disease states where outpatient management will have the greatest impact.
In this pursuit, we are committed to reducing the systemic financial and physical constraints inherent in the highest-cost setting for treatment—the hospital.
We believe the most significant advances in outpatient care will be achieved by applying state-of-the-art science and technologies to current treatment options. In developing unique, ground-breaking approaches, we hope to transform the experience of physicians, patients, caregivers and payors.
Our History
A commitment to innovation.
scPharmaceuticals was formed in 2013 with the intent to advance outpatient care and reduce healthcare costs.
Through ongoing exploration across a range of therapeutic areas and related treatment paradigms, we are working to develop advanced drug formulations, innovative delivery systems, and other complementary solutions. Our lead program, a proprietary formulation of a diuretic for subcutaneous administration, is under development for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization.
Our lead product, FUROSCIX (furosemide injection), has been approved by the FDA. Click here to go to FUROSCIX.com.
Our follow-on programs are focused on subcutaneous administration of select antibacterial agents that have the potential to allow at-home treatment without the need for long-term intravenous catheters.